Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Market Closed 04-11 16:00:00 EDT

4.90

-0.04

-0.81%

盘后4.75

-0.15-3.06%

19:13 EDT

High5.15	Low4.75	Vol33.33K
Open5.04	D1 Closing4.94	Amplitude8.07%
Mkt Cap52.29M	Tradable Cap18.05M	Total Shares10.67M
T/O163.32K	T/O Rate0.90%	Tradable Shares3.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":4.9,"timestamp":1744401600000,"preClose":4.94,"halted":0,"volume":33326,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.9,"latestTime":"19:13 EDT","volume":238,"amount":1146.56,"timestamp":1744413188888},"delay":0,"floatShares":3682843,"shares":10671934,"eps":-20.908733,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-11 16:00:00 EDT","open":5.04,"high":5.1485,"low":4.75,"amount":163318.3153976,"amplitude":0.080668,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-20.908733,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":7,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":4.94,"preHourTrading":{"tag":"盘前","latestPrice":4.86,"preClose":4.94,"latestTime":"08:42 EDT","volume":8,"amount":39.22,"timestamp":1744375351586},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.9,"latestTime":"19:13 EDT","volume":238,"amount":1146.56,"timestamp":1744413188888},"volumeRatio":0.6436649763462755,"impliedVol":1.4551,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2522800575","title":"Avalo Therapeutics Names Michael Heffernan as Board Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2522800575","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522800575?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 22:18","pubTimestamp":1742998714,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics  said Wednesday that Michael Heffernan has been named board chairman, succeeding Garry Neil.Neil will continue as chief executive officer and board member, the company said.Heffernan is the founder and chairman of Collegium Pharmaceutical ,  where he also previously served as president and CEO, Avalo said.Avalo shares were more than 3% higher in recent trading.Price: 8.72, Change: +0.18, Percent Change: +2.12","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","COLL","LENZ","AVTX","BK4139"],"gpt_icon":0},{"id":"2522626879","title":"BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2522626879","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522626879?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:47","pubTimestamp":1742989621,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Therapeutics Appoints Michael Heffernan As Chairman Of The BoardMarch 26 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO THERAPEUTICS APPOINTS MICHAEL HEFFERNAN AS CHAIRMAN OF THE BOARDAVA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA4F4LKB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","LU1093756168.USD","COLL","LU1093756325.SGD","BK4139","TRVI","BHVN","BK4007"],"gpt_icon":0},{"id":"2522398878","title":"Avalo Therapeutics  - Garry Neil to Remain as CEO and Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2522398878","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522398878?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA4F4LKB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2522201998","title":"Press Release: Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2522201998","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522201998?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025  -- Avalo Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors . Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer  of the Company.\"We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth,\" said Dr. Garry Neil, CEO of Avalo Therapeutics. \"Michael's extensive experience in building and leading biopharmaceutical companies, executing successful exits, and driving shareholder value will be invaluable as we advance our pipeline of targeted therapies for immune-mediated diseases, including our lead candidate, AVTX-009, currently in the Phase 2 LOTUS trial for hidradenitis suppurativa . Additionally, I believe it is the right time to separate the role of Chairman an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CEO","BHVN","NQmain","LENZ","AVTX","LU1093756325.SGD","LU1093756168.USD","BK4139"],"gpt_icon":0},{"id":"2522016442","title":"Promising Outlook for Avalo Therapeutics’ AVTX-009 in HS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2522016442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522016442?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 16:57","pubTimestamp":1742893069,"startTime":"0","endTime":"0","summary":"Kambiz Yazdi, an analyst from Jefferies, has initiated a new Buy rating on Avalo Therapeutics (AVTX). Kambiz Yazdi’s rating is based on Avalo Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-outlook-for-avalo-therapeutics-avtx-009-in-hs-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-outlook-for-avalo-therapeutics-avtx-009-in-hs-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2522057525","title":"Avalo Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2522057525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522057525?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 12:20","pubTimestamp":1742876433,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2521239467","title":"Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521239467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521239467?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:35","pubTimestamp":1742819704,"startTime":"0","endTime":"0","summary":"In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Avalo Therapeutics (AVTX – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-avalo-therapeutics-avtx-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-remains-a-buy-on-avalo-therapeutics-avtx-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4127","AVTX","BK4139"],"gpt_icon":0},{"id":"2521469097","title":"Avalo Therapeutics (AVTX) Receives a Hold from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2521469097","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521469097?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 00:07","pubTimestamp":1742486843,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Edward White maintained a Hold rating on Avalo Therapeutics (AVTX – Research Report) today. The company’s shares opened tod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/avalo-therapeutics-avtx-receives-a-hold-from-h-c-wainwright-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/avalo-therapeutics-avtx-receives-a-hold-from-h-c-wainwright-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2520432747","title":"Avalo Therapeutics FY Pretax Profit USD -35.015 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520432747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520432747?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nPLX35E25F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2520437646","title":"Press Release: Avalo Reports 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2520437646","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520437646?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:00","pubTimestamp":1742468400,"startTime":"0","endTime":"0","summary":"-- Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of. -- Appointed Jennifer Riley as Chief Strategy Officer. -- Cash on hand of approximately $135 million as of December 31, 2024. WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024.\"2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,\" said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. \"In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-1<BETA>. We filed our IND application with the FDA, designed and launched the Phase 2 LOTUS trial in hidradenitis suppurativa  and rapidly progressed its initiation, including IND activation in July and enrollment of the first patient in October. Our primary focus in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2520340834","title":"Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520340834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520340834?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:40","pubTimestamp":1742467224,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avalo Therapeutics (AVTX – Research Report) and Korr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-korro-bio-krro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-avalo-therapeutics-avtx-and-korro-bio-krro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTX","BK4137","HCSG","KRRO"],"gpt_icon":0},{"id":"2514326098","title":"Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326098","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326098?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 20:53","pubTimestamp":1740747229,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has an average rating of buy and mean price target of $29.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX","LENZ"],"gpt_icon":0},{"id":"2513262272","title":"Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2513262272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513262272?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 20:50","pubTimestamp":1740142246,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has an average rating of buy and mean price target of $29.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","AVTX"],"gpt_icon":0},{"id":"2508645659","title":"Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508645659","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508645659?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 21:00","pubTimestamp":1738674000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET.Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab  and AVTX-008 . For more information about Avalo, please visit www.avalotx.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avalo-therapeutics-present-oppenheimer-35th-130000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVTX","HCSG","BK4127","BK4137","BK4139","LENZ","OPY"],"gpt_icon":0},{"id":"2500908010","title":"Sector Update: Health Care Stocks Ease Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2500908010","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500908010?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 02:53","pubTimestamp":1735844031,"startTime":"0","endTime":"0","summary":"Health care stocks fell Thursday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund  decreasing 0.3%.The iShares Biotechnology ETF  rose 0.2%.In corporate news, NRX Pharmaceuticals  shares surged 38%. The Hope Therapeutics unit plans to acquire the Kadima Neuropsychiatry Institute.Avalo Therapeutics  shares jumped 14. Jennifer Riley was appointed to the newly created role of chief strategy officer.Neumora Therapeutics  shares plunged 82% after a phase 3 trial of navacaprant to treat major depressive disorder failed to meet the primary endpoint.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IBB","BK4007","NMRA","XLV","BK4139","BK4585","BK4581","NRXP","AVTX"],"gpt_icon":0},{"id":"2500975062","title":"Avalo Therapeutics Names Jennifer Riley as Chief Strategy Officer; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2500975062","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500975062?lang=en_us&edition=full_marsco","pubTime":"2025-01-03 00:02","pubTimestamp":1735833771,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics  said Thursday it appointed Jennifer Riley to the newly created role of chief strategy officer, effective Wednesday.Riley most recently founded Northbrook Consulting, Avalo Therapeutics said.The company's shares were up 9.4% in recent trading.Price: 8.13, Change: +0.70, Percent Change: +9.42","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AVTX","LENZ"],"gpt_icon":0},{"id":"2500940764","title":"Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940764","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940764?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 20:15","pubTimestamp":1735820139,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) appointed Jennifer Riley as Chief Strategy Officer, effective January 1. Riley has over 20 years of leadership experience...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTX","LENZ"],"gpt_icon":0},{"id":"2500884940","title":"Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2500884940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500884940?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 20:00","pubTimestamp":1735819201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nTUA8YMT1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2500947072","title":"Press Release: Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2500947072","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500947072?lang=en_us&edition=full_marsco","pubTime":"2025-01-02 20:00","pubTimestamp":1735819200,"startTime":"0","endTime":"0","summary":"WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization.\"We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer,\" said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. \"Jennifer brings extensive leadership experience, strategic acumen, and deep expertise in immunology, which will be invaluable as we advance our lead asset, AVTX-009, an anti-IL-1<BETA> monoclonal antibody currently in the LOTUS Phase 2 trial for hidradenitis suppurativa. This role is pivotal for Avalo as we refine our commercialization strategies and explore indicati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4214","AN","BK4139","LENZ","AVTX"],"gpt_icon":0},{"id":"2495036235","title":"Avalo Therapeutics (AVTX) Has a New Rating from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2495036235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495036235?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 05:15","pubTimestamp":1735593306,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison initiated coverage with a Buy rating on Avalo Therapeutics (AVTX – Research Report) today and set a price target of $4...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/avalo-therapeutics-avtx-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/avalo-therapeutics-avtx-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.1552},{"period":"1month","weight":-0.3636},{"period":"3month","weight":-0.3},{"period":"6month","weight":-0.4864},{"period":"1year","weight":-0.6889},{"period":"ytd","weight":-0.3405}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052653},{"month":2,"riseRate":0.4,"avgChangeRate":-0.027389},{"month":3,"riseRate":0.3,"avgChangeRate":0.322911},{"month":4,"riseRate":0.3,"avgChangeRate":-0.088518},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.055678},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.014626},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.036742},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.058167},{"month":9,"riseRate":0.555556,"avgChangeRate":0.010251},{"month":10,"riseRate":0.555556,"avgChangeRate":0.13278},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.062453},{"month":12,"riseRate":0.3,"avgChangeRate":-0.048272}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.4","shortVersion":"4.32.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction